Evidence mapPaperPMID 40978277Full record

ReviewAmerican journal of stem cells2025

Epigenetic crosstalk between stem cells and tumors: mechanisms and emerging perspectives.

Wenli Zhou, Xuehai Liu, Zhaoyu Li, Binkui Jia, Xilin Lei, Kai Sun, Pengfei Yang, Shiye He, Di Wang, Haoling Zhang and 1 more

Abstract readReview
In one paragraph

Review in American journal of stem cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wenli ZhouSchool of Clinical Chinese Medicine, Gansu University of Chinese Medicine, Affiliated Hospital of Gansu University of Chinese Medicine Lanzhou 730000, Gansu, China.
Xuehai LiuSchool of Clinical Chinese Medicine, Gansu University of Chinese Medicine, Affiliated Hospital of Gansu University of Chinese Medicine Lanzhou 730000, Gansu, China.
Zhaoyu LiCollege of Acupuncture-Moxibustion and Tuina, Gansu University of Chinese Medicine, Gansu University of Chinese Medicine Lanzhou 730000, Gansu, China.
Binkui JiaSchool of Clinical Chinese Medicine, Gansu University of Chinese Medicine, Affiliated Hospital of Gansu University of Chinese Medicine Lanzhou 730000, Gansu, China.
Xilin LeiSchool of Clinical Chinese Medicine, Gansu University of Chinese Medicine, Affiliated Hospital of Gansu University of Chinese Medicine Lanzhou 730000, Gansu, China.
Kai SunCollege of Acupuncture-Moxibustion and Tuina, Henan University of Chinese Medicine No. 156 Jinshui East Road, Zhengzhou 450000, Henan, China.
Pengfei YangSchool of Clinical Chinese Medicine, Gansu University of Chinese Medicine, Affiliated Hospital of Gansu University of Chinese Medicine Lanzhou 730000, Gansu, China.
Shiye HeSchool of Clinical Chinese Medicine, Gansu University of Chinese Medicine, Affiliated Hospital of Gansu University of Chinese Medicine Lanzhou 730000, Gansu, China.
Di WangDepartment of Biomedical Sciences, Advanced Medical and Dental Institute, Universiti Sains Malaysia Penang 13200, Malaysia.
Haoling ZhangDepartment of Biomedical Sciences, Advanced Medical and Dental Institute, Universiti Sains Malaysia Penang 13200, Malaysia.
Sinong WangSchool of Clinical Chinese Medicine, Gansu University of Chinese Medicine, Affiliated Hospital of Gansu University of Chinese Medicine Lanzhou 730000, Gansu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stem cells possess self-renewal and multipotent differentiation capabilities, exhibiting broad applications in regenerative medicine and tissue homeostasis maintenance. Their fate regulation relies heavily on precise epigenetic mechanisms. Cancer stem cells (CSCs), as key drivers of tumor heterogeneity, recurrence, and drug resistance, share extensive epigenetic features with normal stem cells, forming a complex and dynamic regulatory network. Mechanisms including DNA methylation, histone modification, chromatin remodeling, and ncRNAs collectively sustain stem cell pluripotency and tumor stemness, while aberrant epigenetic alterations serve as core drivers of tumor initiation and progression. In recent years, with the advent of single-cell omics and CRISPR-dCas9 epigenetic editing technologies, epigenetic "crosstalk" between stem cells and tumor cells has been progressively uncovered, especially the multidimensional epigenetic reprogramming induced by the tumor microenvironment (TME) that promotes CSC traits and drug resistance. This review systematically summarizes the epigenetic regulatory mechanisms of stem cells, epigenetic abnormalities in tumors, their interactions, and translational potential in therapeutic strategies, focusing on frontier topics such as reversible epigenetic plasticity, metabolic-epigenetic interplay, and liquid biopsy epigenetic biomarkers. Looking forward, artificial intelligence (AI) and big data analysis are expected to deepen the understanding of epigenetic heterogeneity, driving integrative innovations in precision medicine and regenerative interventions. Comprehensive understanding of the epigenetic crosstalk between stem cells and tumors will provide solid theoretical support and technical pathways for CSC-targeted therapies, epigenetic drug development, and stem cell fate manipulation.

Indexed as

crosstalk mechanismsDNA methylationepigeneticshistone modificationnon-coding RNAStem cells

Identifiers

PMID40978277
PMCPMC12444435

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.